A Study of Bevacizumab and Modified FOLFOX-6 (mFOLFOX-6) in Participants With Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: 5-Fluorouracil (5-FU)
Drug: Bevacizumab
Drug: Levofolinic acid
Drug: Oxaliplatin

Registration Number: NCT01383707

Lead Sponsor: Hoffmann-La Roche

Brief Summary: The multicenter, open-label, single-arm, non-randomized, two-stage Simon's design, phase II study (The CLMO-001 Trial) will evaluate the efficacy and safety of bevacizumab in combination with mFOLFOX-6 (Levofolinic acid, 5-Fluorouracil \[5-FU\] and oxaliplatin) in participants with colorectal cancer and liver metastases. Participants will receive combination therapy of bevacizumab 5 milligrams per kilogram (mg/kg) intravenous (IV) dose and mFOLFOX-6 every 2 weeks during Cycles 1-5 and Cycles 7-12. Participants will receive mFOLFOX-6 alone (without bevacizumab) on Cycle 6. In between Cycle 6 and 7, participants will undergo liver surgery if operable. Thereafter participants will receive bevacizumab (5 mg/kg IV every 2 weeks) alone for 52 weeks (26 cycles) after the end of the post-operative phase (maintenance therapy). At the end of the preoperative treatment phase (Cycles 1-6), participants showing different alternative conditions admitted by the protocol will undergo different management (alternative study designs 1 to 3).

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 77

Inclusion Criteria

Adult participants (male or female), greater than (>) 18 years of age
Histologically confirmed adenocarcinoma of the colon or the rectum
Primitive lesion is at a distance >12 centimeter (cm) from the anal margin for participants with primitive rectal tumor
Measurable metastatic disease confined to the liver
Eastern cooperative oncology group (ECOG) performance status 0-1
No previous chemotherapy for metastatic disease or treatment with drugs targeting vascular endothelial growth factor receptor (VEGF) or epidermal growth factor receptor (EGFR)
Adequate bone marrow, liver and renal function
Urine analysis with proteinuria less than (<) 2+
Use of at least one approved contraceptive method by participants with reproductive potential
Written informed consent from the participants
Surgical criteria for hepatic resection
Adjuvant treatment (either only surgery on primitive tumor or surgery on primitive tumor + adjuvant chemotherapy) must have been concluded greater than or equal to (>/=) 6 months before enrollment

Exclusion Criteria

Presence of extrahepatic metastases
Evidence of lumbo-aortic and celiac lymph nodes involvement
Radiotherapy within 4 weeks before study start
History of inflammatory bowel disease and/or acute/sub-acute bowel occlusion
Presence of serious non-healing wound or ulcer
Evidence of bleeding diathesis or coagulopathy
Clinically significant cardiovascular disease
Uncontrolled hypertension
Current or recent ongoing treatment with anticoagulants
Chronic, daily treatment with high-dose aspirin (>325 mg/day) or other medications known to predispose to gastrointestinal ulceration
Treatment with any investigational drug within 30 days prior to enrollment
Known allergy to Chinese hamster ovary cell proteins, or any of the components of the study medications
Co-existing malignancies diagnosed within the last 5 years with the exception of basal cell carcinoma or cervical cancer in situ
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study treatment start, or anticipation of the need for major surgical procedure during the course of the study. Interval between endoscopic biopsy or colorectal stenting and bevacizumab administration should be evaluated by oncologist/endoscopist
Pregnant or lactating women
Any other disease or condition that contraindicates the use of an investigational drug or puts the patient at high risk for treatment-related complication
Participants with known Human immunodeficiency virus (HIV) infection
Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection with concomitant cirrhosis or undergoing active treatment for the same
Participants who are unable or unwilling to comply with the requirements of the protocol and follow-up procedures

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Bevacizumab + mFOLFOX-6	5-Fluorouracil (5-FU)	Participants will receive combination therapy of bevacizumab 5 mg/kg IV dose and mFOLFOX-6 (Levofolinic acid, 5-FU and oxaliplatin) on Day 1 of every 2 weeks' cycle for 5 cycles (Cycle 1-5), followed by 1 cycle (Cycle 6) of mFOLFOX6 alone (preoperative treatment phase). After 3 weeks of preoperative treatment phase, participants satisfying the surgical criteria for hepatic resectability will undergo a liver metastasectomy. Thereafter participants will receive combination therapy of mFOLFOX-6 + bevacizumab for another 6 cycles (Cycle 7-12); (post-operative treatment phase) followed by bevacizumab alone for 52 weeks (26 cycles) (maintenance therapy).
Bevacizumab + mFOLFOX-6	Bevacizumab	Participants will receive combination therapy of bevacizumab 5 mg/kg IV dose and mFOLFOX-6 (Levofolinic acid, 5-FU and oxaliplatin) on Day 1 of every 2 weeks' cycle for 5 cycles (Cycle 1-5), followed by 1 cycle (Cycle 6) of mFOLFOX6 alone (preoperative treatment phase). After 3 weeks of preoperative treatment phase, participants satisfying the surgical criteria for hepatic resectability will undergo a liver metastasectomy. Thereafter participants will receive combination therapy of mFOLFOX-6 + bevacizumab for another 6 cycles (Cycle 7-12); (post-operative treatment phase) followed by bevacizumab alone for 52 weeks (26 cycles) (maintenance therapy).
Bevacizumab + mFOLFOX-6	Oxaliplatin	Participants will receive combination therapy of bevacizumab 5 mg/kg IV dose and mFOLFOX-6 (Levofolinic acid, 5-FU and oxaliplatin) on Day 1 of every 2 weeks' cycle for 5 cycles (Cycle 1-5), followed by 1 cycle (Cycle 6) of mFOLFOX6 alone (preoperative treatment phase). After 3 weeks of preoperative treatment phase, participants satisfying the surgical criteria for hepatic resectability will undergo a liver metastasectomy. Thereafter participants will receive combination therapy of mFOLFOX-6 + bevacizumab for another 6 cycles (Cycle 7-12); (post-operative treatment phase) followed by bevacizumab alone for 52 weeks (26 cycles) (maintenance therapy).
Bevacizumab + mFOLFOX-6	Levofolinic acid	Participants will receive combination therapy of bevacizumab 5 mg/kg IV dose and mFOLFOX-6 (Levofolinic acid, 5-FU and oxaliplatin) on Day 1 of every 2 weeks' cycle for 5 cycles (Cycle 1-5), followed by 1 cycle (Cycle 6) of mFOLFOX6 alone (preoperative treatment phase). After 3 weeks of preoperative treatment phase, participants satisfying the surgical criteria for hepatic resectability will undergo a liver metastasectomy. Thereafter participants will receive combination therapy of mFOLFOX-6 + bevacizumab for another 6 cycles (Cycle 7-12); (post-operative treatment phase) followed by bevacizumab alone for 52 weeks (26 cycles) (maintenance therapy).

Primary Outcome Measures

Name	Time	Method
Objective Response Rate (ORR) in the Per-protocol Analysis Set (PPAS)	Up to 11 cycles of treatment (up to Week 22)	ORR was defined as the percentage of participants with shrinkage (PR) or disappearance of cancer (CR). Tumor response was evaluated according to the RECIST v1.1. The same method of tumor measurement and assessment had to be used to characterize each lesion throughout the study. Tumor assessment consisted of CT scan (abdomen + pelvis + chest) or CE-MRI (abdomen + pelvis) + non CE-CT (chest) according to the choice of the center. CR, Disappearance of all target lesions; PR, \>=30% decrease in the sum of the longest diameter of target lesions; OR = CR + PR.
Objective Response Rate (ORR) in the Intent-to-treat (ITT) Analysis Set	Up to 11 cycles of treatment (up to Week 22)	ORR was defined as the percentage of participants with shrinkage (partial response \[PR\]) or disappearance of cancer (complete response \[CR\]). Tumor response was evaluated according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). The same method of tumor measurement and assessment had to be used to characterize each lesion throughout the study. Tumor assessment consisted of computerized tomography (CT) scan (abdomen + pelvis + chest) or contrast-enhanced magnetic resonance imaging (CE-MRI) (abdomen + pelvis) + non CE-CT (chest) according to the choice of the center. CR, Disappearance of all target lesions; PR, \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants Achieving No Residual Tumor (R0)/Surgical Margin With Microscopic Residual Tumor (R1) Liver Resection	End of study up to approximately 3 years	The percentage of participants achieving R0/R1 liver resection was defined as the percentage of participants achieving R0 surgery (no residual tumor) plus percentage of participants achieving R1 surgery (surgical margin with microscopic residual tumor).
Overall Survival (OS)	End of study up to approximately 3 years	OS was defined as the time from the date of first study drug administration to the date of death due to any cause. Participants who were alive at the time of the analysis were censored at the last date the participant was known to be alive. OS was calculated as follows: OS (months) = (\[Date of Death - first study drug administration\] + 1)/30
Progression-Free Survival (PFS)	End of study up to approximately 3 years	PFS was defined as the time from the date of first study drug administration to the date of disease progression or death due to any cause, whichever came first. Progression was defined according to RECIST, v1.1 as at least a 20% increase in the sum of diameters of target lesions with an absolute increase of at least 5 mm or the appearance of one or more new lesions. Participants, who did not progress were censored at the date of the last assessment performed. Participants who withdrew from the study without documented progression and for whom an electronic case report form (eCRF) existed as evidence that evaluations had been made, were censored at the date of the last tumor assessment when the participant was known to be progression-free. Participants without post-baseline tumor assessments, but known to be alive were censored at the time of first study drug administration. PFS was calculated: PFS (months) = (\[Date of Event - Date of first study drug administration\] + 1)/30.
Disease-free Interval (DFI)	End of study up to approximately 3 years	DFI was defined as the time from the date of R0/R1 surgery to the date of disease relapse or death due to any cause. Participants who did not progress were considered censored at the date of the last assessment performed. For participants receiving two-stage resection, the date of R0/R1 surgery was the date of the second surgery. Participants, who did not receive surgery and participants without R0/R1 surgery were censored at Day 1. DFI was calculated as follows: DFI (months) = (\[Date of R0/R1 surgery - Date of 1st relapse/Death\] + 1)/30

Trial Locations

Locations (11): Irccs Ospedale San Raffaele;Oncologia Medica
🇮🇹
Milano, Lombardia, Italy
Centro Catanese Di Oncologia; Oncologia Medica
🇮🇹
Catania, Sicilia, Italy
IRCCS Istituto Nazionale Tumori Fondazione Pascale; Oncologia Medica A
🇮🇹
Napoli, Campania, Italy
Fondazione IRCCS Policlinico San Matteo
🇮🇹
Pavia, Lombardia, Italy
Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica
🇮🇹
Bologna, Emilia-Romagna, Italy
Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica
🇮🇹
Milano, Lombardia, Italy
Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia
🇮🇹
Milano, Lombardia, Italy
A.O. Universitaria Policlinico Di Modena; Ematologia
🇮🇹
Modena, Emilia-Romagna, Italy
Azienda Ospedaliera Sant' Antonio Abate; Divisione di Oncologia
🇮🇹
Gallarate, Lombardia, Italy
Az Ospedaliera Nuovo Garibaldi Quartiere Nesima; Oncologia Medica
🇮🇹
Catania, Sicilia, Italy
Ospedali Riuniti Di Ancona; Oncology
🇮🇹
Ancona, Marche, Italy